Legislative Status of GHB Worldwide > 자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

GHB, or gamma-hydroxybutyrate, is a therapy used for the management of cataplexy. However, it has also gained negative publicity as a drug of misuse and has been linked to several social and legal concerns. As a result, many countries have established rules to control the possession of GHB.

In the U.S., GHB was listed as a most restrictive classification in 1990, which is the most restrictive classification according to US federal law. However, in 2002, GHB was rescheduled to Schedule I to Schedule III, which allowed for certain therapeutic uses, including the management of cataplexy. This change in scheduling status was made due to the implementation of new models and the implementation of safety measures to minimize the risk of misuse.

In the Britain, GHB is classified as a Schedule B substance under the Misuse of Drugs Act 1971, which means that distributing GHB without a valid license can result in fines. Class C substances are considered to be the lesser serious of the controlled substances, but crimes involving GHB can still carry consequences of up to 14 years in prison.

In Canada, GHB was listed as a most restrictive classification under the Controlled Drugs and Substances Act in 2003, which gave the Canadian government the authority to regulate its distribution. In order to obtain GHB, Canadians typically require a license from a qualified medical practitioner, which is necessary for legitimate treatment of cataplexy.

In down under, GHB is classified as a most restrictive scheduling category, which is the least restrictive scheduling category under state and federal laws. This classification prohibits the possession of GHB except for specific purposes, and possession without a license can lead to lengthy prison sentences.

In Deutschland, GHB is classified as a lesser control, which places it under greater restrictions than substances classified as Tier 3 but fewer restrictions than Tier 1 substances. The handling of GHB in Germany requires a license from the regulatory authorities, and illicit use can result in sentence and imprisonment.

In France, ghb kaufen is considered a harmful substance under the Loi du 31 décembre 1970, which means that it has serious health risks, and as such is controlled and dispensed by prescription and license, outside therapeutic use, possible results of arrest as recidivists 5 years may be handed. In Scandinavia, it is classified as a "strong drug" which essentially gives the same severe use such as drugs.

It is important to note that the ever-shifting social and atmosphere often gives health organizations and legal regulatory commissions much to debate. Under such considerations GHB, often for specific purposes is discovered to be of growing use, and also, that many current controls can often be proven to be eventually ineffective. As existing studies and evidence evolve around GHB they find evidence supporting GHB's range in potential therapeutic uses worldwide, a dialogue ultimately that calls for continued reflection and discussions in society, including severity and alteration as appropriate legal responses.